Angelo Scanu Memorial

C. Edelstein, G. Getz, S. Marcovina, J. Albers, M. Koschinsky
{"title":"Angelo Scanu Memorial","authors":"C. Edelstein, G. Getz, S. Marcovina, J. Albers, M. Koschinsky","doi":"10.1161/atvbaha.118.311203","DOIUrl":null,"url":null,"abstract":"Angelo Scanu spent almost the whole of his illustrious scientific career at the University of Chicago. Actually, he had 2 distinguished careers there: one devoted to plasma HDL (high-density lipoprotein) and the other to Lp(a) (lipoprotein(a)). Angelo had come to the United States in 1955 on a Fulbright Scholarship, working with Irvine Page at the Cleveland Clinic and with Walter Hughes at the Brookhaven National Laboratories. It was at this time he began his pioneering work on lipoproteins, developing a delipidation procedure that yielded apolipoproteins in essentially a lipidfree state. This breakthrough opened up the field of apolipoprotein research. He came to the University of Chicago in 1961 to do his American internship in internal medicine—a second internship, having done the first one in Italy, where he had graduated cum laude from Sassari University Medical School in 1949. Angelo then joined the faculty in the Department of Medicine at the University of Chicago, where he remained until his retirement in 2011. For the first 25 years of his research career, his focus was HDL, including the isolation and characterization of the structures of its 2 major apoproteins, A-I and A-II. Using innovative physicochemical methods, Angelo and his colleagues elucidated the role of the apolipoproteins in HDL structure. As a visiting investigator at CNRS (Centre National de la Recherche Scientifique), Gif-sur Yvette, France, he learned to apply small-angle X-ray scattering to the examination of lipoprotein structure. Along with Dr Vittorio Luzzati, these studies led to a series of important new findings on the structural organization of low-density lipoprotein and HDL. This venture highlighted Angelo’s recognition of the importance of physical chemistry to the full understanding of lipoprotein structure—a view highlighted by his collaboration with Francois Kezdy, who was a close collaborator at the University of Chicago. Angelo was also a principal investigator in the Specialized Center of Research on Atherosclerosis where he studied the lipoproteins, lowdensity lipoprotein, and HDL of nonhuman primates. In the mid 1980s, the focus of Angelo’s laboratory shifted to the second theme of his research, Lp(a). In 1984, the group reported on the heterogeneity of Lp(a) particle size, which they correctly attributed to differently sized apo(a) (apolipoprotein(a)) moieties. In 1987, through a collaboration with Genentech, Inc, Angelo and his colleagues provided the first report of the unexpected similarity between the apo(a) component of Lp(a) and the fibrinolytic proenzyme plasminogen. The partial protein sequence data indicated the presence in apo(a) of domains corresponding to plasminogen kringle IV, kringle V, and protease sequences; the latter domain was shown to be inactive in apo(a). This work led to a publication in Nature in 1989, where Angelo’s group showed that Lp(a) inhibits the binding of plasminogen to vascular cells—an important mechanism for the proposed antifibrinolytic effect of Lp(a). He and his collaborators were also the first group to report in 1989 the development of an ELISA method to measure Lp(a) that was insensitive to plasminogen and to report that on a weight basis, there was a difference in immunoreactivity of Lp(a) particles with different apo(a) isoforms. Equivalent reactivity was observed when protein concentration was expressed on molar basis and the article stressed the need for the development of appropriate standards to minimize the heterogeneity of Lp(a), which remains an area of focus in the field. The group also contributed a significant body of knowledge to our This In Memoriam also appears in the Journal of Lipid Research. From the Department of Medicine, Retired (C.E.), and Department of Pathology (G.S.G.), University of Chicago, IL; Northwest Lipid Metabolism Research Laboratories, University of Washington, Seattle (S.M.M., J.J.A.); and Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada (M.K.). Correspondence to Celina Edelstein, BA, University of Chicago, Chicago, IL. E-mail celinaed@icloud.com Angelo Scanu Memorial Tribute to Angelo Scanu (1924–2018)","PeriodicalId":8404,"journal":{"name":"Arteriosclerosis, Thrombosis, & Vascular Biology","volume":"53 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arteriosclerosis, Thrombosis, & Vascular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/atvbaha.118.311203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Angelo Scanu spent almost the whole of his illustrious scientific career at the University of Chicago. Actually, he had 2 distinguished careers there: one devoted to plasma HDL (high-density lipoprotein) and the other to Lp(a) (lipoprotein(a)). Angelo had come to the United States in 1955 on a Fulbright Scholarship, working with Irvine Page at the Cleveland Clinic and with Walter Hughes at the Brookhaven National Laboratories. It was at this time he began his pioneering work on lipoproteins, developing a delipidation procedure that yielded apolipoproteins in essentially a lipidfree state. This breakthrough opened up the field of apolipoprotein research. He came to the University of Chicago in 1961 to do his American internship in internal medicine—a second internship, having done the first one in Italy, where he had graduated cum laude from Sassari University Medical School in 1949. Angelo then joined the faculty in the Department of Medicine at the University of Chicago, where he remained until his retirement in 2011. For the first 25 years of his research career, his focus was HDL, including the isolation and characterization of the structures of its 2 major apoproteins, A-I and A-II. Using innovative physicochemical methods, Angelo and his colleagues elucidated the role of the apolipoproteins in HDL structure. As a visiting investigator at CNRS (Centre National de la Recherche Scientifique), Gif-sur Yvette, France, he learned to apply small-angle X-ray scattering to the examination of lipoprotein structure. Along with Dr Vittorio Luzzati, these studies led to a series of important new findings on the structural organization of low-density lipoprotein and HDL. This venture highlighted Angelo’s recognition of the importance of physical chemistry to the full understanding of lipoprotein structure—a view highlighted by his collaboration with Francois Kezdy, who was a close collaborator at the University of Chicago. Angelo was also a principal investigator in the Specialized Center of Research on Atherosclerosis where he studied the lipoproteins, lowdensity lipoprotein, and HDL of nonhuman primates. In the mid 1980s, the focus of Angelo’s laboratory shifted to the second theme of his research, Lp(a). In 1984, the group reported on the heterogeneity of Lp(a) particle size, which they correctly attributed to differently sized apo(a) (apolipoprotein(a)) moieties. In 1987, through a collaboration with Genentech, Inc, Angelo and his colleagues provided the first report of the unexpected similarity between the apo(a) component of Lp(a) and the fibrinolytic proenzyme plasminogen. The partial protein sequence data indicated the presence in apo(a) of domains corresponding to plasminogen kringle IV, kringle V, and protease sequences; the latter domain was shown to be inactive in apo(a). This work led to a publication in Nature in 1989, where Angelo’s group showed that Lp(a) inhibits the binding of plasminogen to vascular cells—an important mechanism for the proposed antifibrinolytic effect of Lp(a). He and his collaborators were also the first group to report in 1989 the development of an ELISA method to measure Lp(a) that was insensitive to plasminogen and to report that on a weight basis, there was a difference in immunoreactivity of Lp(a) particles with different apo(a) isoforms. Equivalent reactivity was observed when protein concentration was expressed on molar basis and the article stressed the need for the development of appropriate standards to minimize the heterogeneity of Lp(a), which remains an area of focus in the field. The group also contributed a significant body of knowledge to our This In Memoriam also appears in the Journal of Lipid Research. From the Department of Medicine, Retired (C.E.), and Department of Pathology (G.S.G.), University of Chicago, IL; Northwest Lipid Metabolism Research Laboratories, University of Washington, Seattle (S.M.M., J.J.A.); and Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada (M.K.). Correspondence to Celina Edelstein, BA, University of Chicago, Chicago, IL. E-mail celinaed@icloud.com Angelo Scanu Memorial Tribute to Angelo Scanu (1924–2018)
安吉洛·斯坎努纪念馆
安吉洛·斯坎努在芝加哥大学度过了几乎整个辉煌的科学生涯。实际上,他在那里有两个杰出的职业:一个致力于血浆HDL(高密度脂蛋白),另一个致力于Lp(a)(脂蛋白)。安吉洛于1955年获得富布赖特奖学金来到美国,在克利夫兰诊所与欧文·佩奇一起工作,在布鲁克海文国家实验室与沃尔特·休斯一起工作。正是在这个时候,他开始了他在脂蛋白方面的开创性工作,开发了一种脱脂程序,在本质上是无脂状态下产生载脂蛋白。这一突破开辟了载脂蛋白研究领域。1961年,他来到芝加哥大学,在美国进行内科实习——这是他第二次实习,第一次实习是在意大利,1949年,他以优异的成绩从意大利萨萨里大学医学院毕业。随后,他加入了芝加哥大学医学系,直到2011年退休。在他研究生涯的前25年里,他的研究重点是HDL,包括其2个主要载脂蛋白A-I和A-II的分离和结构表征。利用创新的物理化学方法,Angelo和他的同事阐明了载脂蛋白在高密度脂蛋白结构中的作用。作为法国国家科学研究中心(CNRS)的访问研究员,他学会了将小角度x射线散射应用于脂蛋白结构的检查。与Vittorio Luzzati博士一起,这些研究导致了一系列关于低密度脂蛋白和高密度脂蛋白结构组织的重要新发现。这次冒险凸显了安杰洛对物理化学对全面了解脂蛋白结构的重要性的认识——他与芝加哥大学的密切合作者弗朗索瓦·凯兹迪(Francois Kezdy)的合作凸显了这一观点。Angelo也是动脉粥样硬化专业研究中心的首席研究员,在那里他研究了非人类灵长类动物的脂蛋白、低密度脂蛋白和高密度脂蛋白。在20世纪80年代中期,Angelo的实验室的重点转移到他的研究的第二个主题,Lp(a)。1984年,该小组报道了Lp(a)颗粒大小的异质性,他们正确地将其归因于不同大小的载脂蛋白(a)部分。1987年,通过与Genentech公司的合作,Angelo和他的同事首次报告了Lp(a)的载脂蛋白(a)成分与纤溶酶前纤溶酶原之间意想不到的相似性。部分蛋白序列数据显示,载脂蛋白a中存在与纤溶酶原kringle IV、kringle V和蛋白酶序列相对应的结构域;后一结构域在载脂蛋白(a)中无活性。这项研究成果于1989年发表在《自然》杂志上,Angelo的研究小组发现Lp(a)抑制了纤溶酶原与血管细胞的结合——这是Lp(a)抗纤溶作用的重要机制。1989年,他和他的合作者也是第一个报告开发了一种ELISA方法来测量对纤溶酶原不敏感的Lp(a),并报告了在重量基础上,具有不同载脂蛋白(a)亚型的Lp(a)颗粒的免疫反应性存在差异。当蛋白质浓度以摩尔为基础表达时,观察到等效的反应性,文章强调需要制定适当的标准,以尽量减少Lp(a)的异质性,这仍然是该领域的一个重点领域。该小组还为我们的“纪念”贡献了重要的知识体系,这篇文章也发表在《脂质研究杂志》上。芝加哥大学医学系退休(C.E.)和病理科(G.S.G.);西北脂质代谢研究实验室,华盛顿大学,西雅图(s.m.m., J.J.A.);加拿大伦敦西安大略大学舒利希医学与牙科学院罗伯特研究所(M.K.)。与塞琳娜·埃德尔斯坦的通信,文学学士,芝加哥大学,芝加哥,伊利诺斯州。E-mail celinaed@icloud.com安杰洛·斯坎努纪念馆致敬安杰洛·斯坎努(1924-2018)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信